



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated 1<sup>st</sup> June, 2018**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Receipt of Establishment Inspection Report (EIR) US FDA -Reg.**

**Ref: Our letter dated 26<sup>th</sup> March 2018 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for Company's Gagillapur facility located at Hyderabad, Telangana, India.

This facility was inspected by US FDA in March 2018 without any 483 observations during the inspection. Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

**For GRANULES INDIA LIMITED**

*T. Chaitanya*  
  
**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**